Prévention secondaire médicamenteuse après infarctus du myocarde en France : facteurs associés à l'adhérence et impact sur la mortalité et réhospitalisations à 30 mois
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Background
Between 1992 and 2002, the three French registers of acute coronary syndromes, obtained from the Multinational monitoring of trends and determinants in cardiovascular disease (MONICA) Project, observed an overall reduction in mortality (particularly hospital mortality), but not in the incidence of coronary disease. This can be explained partly by the increase and improvement in recommended invasive and noninvasive treatments, as in other countries [1] [2] [3] . In 2007, the French National Authority for Health published guidelines for coronary disease management. As in many international recommendations on secondary prevention for patients with a myocardial infarction (MI), evidence-based treatment (EBT) combining beta-blockers, statins, aspirin and/or clopidogrel, and angiotensin-converting enzyme inhibitors (ACEIs) is recommended in France [4] . These recommendations are based on the results of clinical trials or registries that observed decreased rates of cardiovascular death and serious cardiac events, as well as an advantageous cost-effectiveness ratio, for each medication class and their combination [5] . 'Real-world' studies in North America and Europe have observed a temporal increase in use of EBT. For France, our previous study among 11,671 patients hospitalized for MI during the first semester of 2006 reported a globally satisfactory use of EBT in the 6 months after discharge: 82% of patients were reimbursed for beta-blockers, 92% for antiplatelets, 85% for statins, 80% for ACEIs/angiotensin receptor blockers (ARBs) and 62% for all four classes [6] . However, several characteristics were associated with lower rates of prescription and refund of EBT (e.g. older age, female sex, presence of comorbid conditions or associated treatments, lower level of healthcare coverage, management at non-university hospitals, lack of follow-up by a cardiologist, or coronary artery bypass surgery, geographical region) [6] [7] [8] [9] [10] [11] [12] [13] [14] . Beyond initial EBT prescription after MI, long-term adherence to treatment is known to play a crucial role in survival improvement. Nevertheless, few 'real-world' results have been reported regarding the impact on mortality of each class and on the EBT combination after MI [15, 16] .
The objectives of this second study were to evaluate the level of long-term adherence to EBT, as well as the factors correlated with each medication class, and its impact on survival after hospitalization for MI in France.
Methods

Sources of data
In France, the general health insurance scheme covers 70% of the population (i.e. 48 million people in 2006) and its information system (système national d'informations inter-régimes de l'assurance maladie [SNIIRAM]) contains individualized, anonymous and exhaustive data on all health-spending reimbursements. Further information is recorded, such as full refund for people with one of 30 long-term diseases (LTDs), including heart disease, and the existence of full healthcare coverage for low earners (below an income ceiling of D 7500 per year). Moreover, vital status (all-cause mortality) stemming from the French National Institute of Statistics and Economic Studies is available in the SNIIRAM system. This information can be linked to the French hospital discharge database (programme de médicalisation des systèmes d'information [PMSI]), which provides medical information for all patients discharged from both private and public hospitals, including the World Health Organization International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnostic codes.
Patient population
All hospitalizations from January to June 2006 with a diagnosis-related group of MI were selected from the PMSI data on short-term hospital stays. We selected all patients covered by the general health insurance scheme. For each patient, the first hospital admission for MI in the first half of 2006 was considered as the index hospital admission. These data were linked, using a common, anonymous patient number, to the corresponding records in the reimbursement database. Patients who died or were lost to follow-up during the first 6 months were excluded from the analysis, because their adherence behaviour could not be determined accurately. Possible reasons for loss to follow-up included a move abroad and a change in social security number (e.g. for widowed women). If a patient was lost to follow-up beyond 6 months, they were included in the analysis as a censored observation, with the date of the last refund as the censoring point. All patients were followed for up to 30 months. For each EBT class (beta-blockers, statins, ACEIs/ARBs, aspirin/clopidogrel), the analysis included all patients who had at least one refund for this medication class after index admission. For the medication combination, all patients with at least one refund for each class were included.
Variables studied
For each index hospital admission, the following data were collected: sex, age, use of angioplasty, stent implantation, and coronary artery bypass graft procedures during the index hospital admission or within 30 days after discharge, according to the classification of medical procedures used in France. Prior hospitalization for cardiovascular events (coronary artery disease [acute MI, angina pectoris, coronary atherosclerosis], coronary bypass surgery and stent implantation procedures) were identified using a specific diagnosis-related group notified for hospital stays in the 6 months preceding index hospital admission. The presence of a cardiovascular LTD 6 months prior to index hospital admission and full healthcare coverage for low earners were also recorded.
Comorbid conditions were sought and defined in several ways, taking into account the entire period between 2005 and 2008. Patients with depression or Parkinson's disease were identified through reimbursements of specific medications by the presence of two dispensations at most, within a 6-month interval. Diabetes and pulmonary diseases were characterized by the reimbursement of indicator medications at least twice over one calendar year. Inflammatory symptoms were identified by regular reimbursements of steroidal or non-steroidal anti-inflammatory drugs (i.e. the proportion of days covered by a filled prescription greater than 80% in the 30-month follow-up period). For psychiatric disorders and chronic liver disease, the occurrences of specific LTDs were used. For neoplasia, the following indicators were used: radiotherapy or chemotherapy sessions, hospital admission with a main diagnosis of cancer, or a specific cancer LTD beginning in 2004 or later. Alzheimer's disease was defined by the specific LTD or by reimbursements of specific medications issued at least twice within one calendar year or by hospital admission with a specific dementia diagnosisrelated group. For chronic renal disease, patients with a 'chronic renal' LTD and/or treated with dialysis and/or with immunosuppressive drugs were selected.
For each EBT class, drug adherence was assessed by a medication possession ratio during the 30-month follow-up period after hospitalization for MI, i.e. between the day after index hospital discharge and the last day of presence in the study (end of follow-up or lost to follow-up). More specifically, we used two different measures depending on the medication class. For beta-blockers, statins and ACEIs/ARBs, we calculated the proportion of days on which a patient had pills available (considering one pill per day as necessary). For aspirin/clopidogrel, where combined treatment is not unusual, adherence was measured by the ratio of the number of dates of supply to the number of months in the study. For each medication class, patients were classified in two groups: adherent patients (adherence measure > 80%) and nonadherent patients (otherwise). A patient was considered to be adherent to the combined treatment if they were adherent to each of the four medication classes. Moreover, consumption during the 6 months before the index hospital admission was considered to be 'regular' after at least three medication refunds. Health outcome was assessed as death or hospital readmission for acute coronary syndrome (ACS) within the follow-up period.
Statistical analysis
For each recommended class of medication, as well as for their combined use, we compared adherent and nonadherent patients according to their baseline characteristics, in-hospital management and use of concomitant medications after index hospital admission, by calculating the proportions of nonadherent patients for each characteristic and the crude odds ratios (adherent versus nonadherent patients). To explore the crude relationship between age and adherence in more detail, we used locally-weighted linear regression, highlighting non-linear trends graphically. Adjusted odds ratios were determined using multivariable logistic regression models as a function of age, sex, full healthcare coverage for low earners, comorbidities, prior hospitalization for cardiovascular condition, 'cardiovascular' LTD, use of the considered medication class in the 6 months before index admission, myocardial revascularization procedures during and 1 month after the index admission, deliveries and adherence to the other medication classes.
For each medication class, crude ACS-free survival rates in adherent and in nonadherent patients were calculated using the Kaplan-Meier method. For further comparisons, hazard ratios were derived from Cox proportional hazards models, both univariate and multivariable (using the above-mentioned characteristics as covariates). In addition, adjusted ACS-free survival rates were calculated with their 95% confidence interval (CI) [17] .
A P-value less than 0.05 was considered significant. All analyses were performed using SAS software (SAS version 9.1.3, SAS Inc., Cary, NC, USA).
Results
In the first half of 2006, there were 24,075 hospital stays with a diagnosis-related group of MI in France. The anonymous patient number used for matching was missing for 1701 (7.1%) of these patients and, of the 22,374 remaining, only 14,788 (66.1%) admissions involved 14,007 patients covered by the general health insurance scheme. Of these, 1418 (10.1%) patients died during the index hospital admission, 769 (5.5%) died in the 6 months after discharge and 216 (1.5%) were lost to follow-up within 6 months. So, 11,604 patients were still present after 6 months, and within the 30-month follow-up period, 10,501 (90.5%) had at least one refund for statins, 9937 (85.6%) for beta-blockers, 9823 (84.7%) for ACEIs/ARBs and 11,056 (95.3%) for aspirin or clopidogrel. A total of 8249 (71.1%) patients had refunds for all four medication classes.
Determinants of adherence
The proportions of patients with an insufficient adherence measure (< 80% during the observation period) were 32.0% for beta-blockers, 24.0% for statins, 22.7% for ACEIs/ARBs, 18.3% for aspirin/clopidogrel and 50.0% for combined EBT. Tables 1 and 2 show the relationships between drug adherence and patient characteristics. After adjustment for these patient characteristics, adherence to EBT was found to be decreased significantly by the following factors: age greater than 74 years; comorbidities (neoplasia, renal disease, chronic obstructive pulmonary disease, Alzheimer's disease, Parkinson's disease and depression); and full healthcare coverage for low earners. Conversely, prior combination refund and stent implantation before or during index hospitalization increased adherence. For each separate medication class, adherence was associated positively with adherence to the three other classes as well as with prior use of the medication class under consideration. Moreover, adherence to beta-blockers was decreased in patients with renal disease, chronic obstructive pulmonary disease or depression. Adherence to statins was decreased by presence of diabetes mellitus, Alzheimer's disease, depression or full refund for cardiovascular disease. For ACEIs/ARBs, adherence was decreased by renal disease or depression. Fig. 1 illustrates the unadjusted relationship between age and medication adherence. For all medication classes, inverse U-shaped curves were found, with the highest adherence rates between 55 and 75 years. Note that an age younger than 45 years remained negatively related to adherence after adjustment, but was significant only for aspirin/clopidogrel.
Mortality and rehospitalization for acute coronary syndrome
For each medication class, as well as for combined EBT, the unadjusted rates of mortality and readmission for ACS after the 30-month follow-up period were significantly lower in adherent patients, as illustrated in Fig. 2 . After direct adjustment for patient characteristics, the differences in ACS-free survival between adherent and nonadherent patients became smaller, but remained significant, except for beta-blockers. For statins, adjusted rates of death or ACS readmission were 13.1% (95% CI 11.8-14.3) in nonadherent patients and 8.1% (7.5-8.7) in adherent patients. The adjusted risks were, respectively, 9.5% (8.6-10.4) and 10.3% (9.6-11.0) for beta-blockers, 13.1% (11.8-14. 3) and 10.4% (9.7-11.0) for ACEIs/ARBs, 12.6% (11.4-13.9) and 10.5% (9.9-11.2) for aspirin/clopidogrel, and 9.9% (9.1-10.8) and 6.7% (5.9-7.5) for combined EBT. Table 3 contains the hazard ratios obtained from multivariable Cox models, adjusting for patient characteristics. In agreement with the adjusted rates of mortality or ACS readmission, the adjusted hazard ratios of nonadherence were significantly greater than 1 for all medication classes, except for beta-blockers. For example, the adjusted hazard ratio of nonadherence to statins was 1.58 (95% CI 1.37-1.81). In addition, medication use before index admission for MI decreased mortality and readmission for ACS significantly for each medication class, but not for combined EBT. Note that only a small number of patients were treated with combined EBT before index admission (7.3% of the 8249 users of combined EBT after MI). By comparison, 26.1% of the 10,501 statin users had been treated with statins previously. More- over, the ACS-free survival in users of each medication class was significantly related to concomitant use of the three other medication classes. With respect to their concomitant medication use, patients were classified as 'non-users', 'nonadherent users' or 'adherent users' for each medication class. So, concomitant adherence with statins is significantly related to ACS-free survival in the users of each of the other medication classes. The same holds for concomitant adherence to ACEIs/ARBs and to aspirin/clopidogrel. By contrast, concomitant adherence to beta-blockers is not significantly related to ACS-free survival in the users of another medication class, but non-use of beta-blockers is related to ACS-free survival.
Discussion
This large, population-based, observational study on adherence to EBT in the 30 months after MI combined hospitalization and reimbursement data for patients. The study documents lower adherence for older age, specific comorbid conditions and low income with full healthcare coverage, and higher adherence for patients with stent implantation and prior use of EBT. In addition, a strongly improved survival rate was found in patients adherent to combined EBT, but also, separately, in adherent users of statins, ACEIs/ARBs and aspirin/clopidogrel. In contrast, adherence to betablockers had no significant relationship to survival after adjustment.
Adherence
Proportions of nonadherent patients reported by this study are similar to those from other studies, with around 30% for beta-blockers and around 20% for statins and ACEIs/ARBs [11, 15, 18] . Few data have been reported for aspirin/clopidogrel (and consequently for the whole EBT combination) because aspirin is available over the counter and/or is not reimbursed in most countries. However, a study found that only 20% of the patients took the combination of aspirin, beta-blockers and statins consistently [19] . Another study reported that 12% of patients discontinued this combination 1 month after discharge [20] . In France, aspirin is available at a specific dosage for cardiovascular risk prevention and each delivery is reimbursed. Consequently, our data should contain all aspirin deliveries of interest. The reasons for underprescription range from absolute to possible relative contraindications (e.g. chronic obstructive pulmonary disease and beta-blockers, as found in this study) to reluctance to take additional medication in patients already receiving a number of non-cardiovascular drugs. In theory, more than 95% of patients may be treated by statins, Table 3 Association of adherence to evidence-based treatment with mortality or readmission for acute coronary syndrome in the 30-month follow-up period after hospitalization for myocardial infarction in France. as true contraindications are rare. The same applies for ACEIs/ARBs, whereas contraindications are more common for beta-blockers. Furthermore, adverse reactions or intolerance are also likely to have an influence on medication adherence. For example, we did not find adherence differences between men and women, except for beta-blockers, which could be explained by sexual side effects such as impotence or loss of libido. Older age is related to a lower use of preventive treatments [9, 15, 21, 22] . In our study, the fall in adherence to combined EBT over the age of 75 years seems to be due mainly to low adherence to statins. For both combined EBT and statins, the negative effect of older age on adherence remained significant after adjustment for comorbidities and myocardial revascularization procedures. Reasons for low adherence range from possible contraindications to reluctance to take additional medication in patients receiving numerous non-cardiovascular drugs. At the other end of the spectrum, the lower adherence to each class of secondary prevention therapy in very young MI patients (< 45 years) may appear surprising. However, this association did not remain significant after adjustment for sex, comorbidities and myocardial vascularization procedures, except for aspirin/clopidogrel. One possible explanation could be that occurrence of an MI among the youngest patients is linked with more comorbidities and risk factor exposure, in association with poorer health management, and consequently, with an increased risk of another MI; this has been pointed out previously [23] . Also, younger, active patients might be more reluctant to take lifelong secondary prevention medication. Finally, there was a higher proportion of low-income patients in the younger population -a factor related to poorer adherence to chronic medications; this might explain why the impact of younger age on adherence was no longer significant after multivariable adjustment, including social variables.
Beta-blockers
- - - - - - - - Statins - - 1.60 e 1.20 c - - - - - - ACEIs/ARBs - - - - 1.96 e 1.25 d - - - - Aspirin/clopidogrel - - - - - - 2.33 e 1.40 e - - Combination - - - - - - - - 1.91 e 1.21
Concomitant medication use after index admission for MI
In a previous study on diabetic patients from the same population, we found similar persistence rates after hospitalization at 6 months between diabetic patients (85.5%) and non-diabetic patients (85.2%), adjusted for age and sex [24] . During the 6 months before their hospitalization for MI, diabetic patients had statins more often than non-diabetic patients (40.8% vs 19.9%, respectively), with adjustment for age and sex. This could argue for large primary prevention among diabetics. But in this study, diabetic patients had 30 months of adherence, similar to non-diabetics, except for statins, despite being at higher risk of an ischaemic event. This could suggest more frequent secondary or adverse effects specific to diabetic patients, with more frequent interruption.
Others comorbidities were related to lower adherence, such as patients with chronic renal disease, who had a significantly lower adherence rate for combined EBT and specifically for beta-blockers and ACEIs/ARBs, as reported in another study in patients undergoing dialysis [25] . Low EBT adherence rates in patients with severe comorbidities may be explained by consideration of the substantial risk of dying irrespective of the coronary artery disease, such as for neoplasia, Alzheimer's disease and Parkinson's disease. There is no question that prescribing secondary prevention medications in patients with severe comorbidities may represent a true ethical issue for prescribers, discussion of which is beyond the scope of the present study. Lastly, the association between the use of antidepressant medications and low adherence should be noted, because it involved about 20% of our population [6] .
The positive effect of financial reimbursement on prevention or care consumption has already been documented widely. In our earlier study [6] , we observed that low earners with full healthcare coverage had similar levels of combined EBT persistence at 6 months. But, their adherence at 30 months was no longer similar; it was lower for each medication class, except for beta-blockers, even after adjustment for some comorbidities and myocardial revascularization procedures. In theory, in France, low earners have free access to inpatient and outpatient care. Low adherence could be explained by a lack of adjustment for comorbidities, because these patients had a wide range of comorbidities, with high hospitalization rates [26] .
Nevertheless, true contraindications are rare for statins and ACEI/ARBs, whereas they are more common for aspirin/clopidogrel. This is also the case for beta-blockers, to which low earners had higher adherence. This could reflect clinicians' attitudes to patients who are receiving many medications, preferring to reserve beta-blocker monotherapy for individuals with more cardiovascular risks, such as hypertension.
EBT was used more often in patients who underwent myocardial revascularization, mainly by stent implantation, prior to or after the index hospitalization, as noted previously at 6 months [27] . For each medication class, as well as for combined EBT, patients with medication use before index admission were more often adherent after MI. Nonadherence to a given medication class was related to nonadherence to the other medication classes, a finding that has also been reported previously [11] .
Mortality
Clinical trials have demonstrated the positive effects of EBT on survival after MI. In our study, adherence was related to a 38% reduction in all-cause mortality and ACS readmission rate at 30 months for statins, a 21% reduction for ACEIs/ARBs and a 16% reduction for aspirin/clopidogrel. With regard to statins, the reduction is higher than that reported by clinical trials (around 20%) [28] . One hypothesis is that observational studies are conducted mainly in an unselected population, reflecting the overall benefits of statins. Prior statin use was also related to improved clinical outcome, but this effect disappears with early withdrawal [29] .
In this study, adherence to beta-blockers was not significantly related to ACS-free survival. The incremental survival benefits associated with beta-blocker use are under debate, with the use of reperfusion therapies and new drugs added to the EBT combination. This debate focuses more specifically on the true benefit of beta-blockers in people who have sustained an AMI at low risk, with complete reperfusion and preserved left ventricular function. Unfortunately, specific clinical and disease severity data were not available in our study. A similar study that included elderly MI survivors found no effect of intermediate adherence to beta-blockers (40-79%) compared with high adherence (≥ 80%) and a significant effect for low adherence (< 40%) but with a weak magnitude [12] . This last study also found a significant positive effect for prior use of beta-blockers. Nevertheless, lack of beta-blocker use after MI is associated with low survival. This could be explained by an indication bias, with more severe clinical status or frequent limitations and contraindications for patients with no beta-blocker refunds. We tried to minimize this confounding effect by including patients with at least one refund in each medication group after MI. Nevertheless, those with few refunds may have a different clinical status. Beta-blocker benefit could be time-dependent, with marked mid-term and long-term effects. A study by Huikuri et al. reported that sudden death only occurred 20 months after MI [30] .
Strengths and limitations
The strength and originality of this study are derived from the cross-linkage of various large medico-administrative databases, thereby providing comprehensive hospitalization and medical consumption data. Because the general health insurance scheme covers 70% of the French population, our data are likely to be fairly representative of the level of care in France in 2006, although we cannot exclude that populations covered by other health insurance schemes might have been treated differently. Access to reimbursement databases allowed us to perform adjustment for concomitant non-cardiovascular diseases. The reimbursement database is comprehensive for all medications purchased and reimbursed; in contrast with telephone or mail surveys, there is no recall bias and a low non-responder rate. It does not take into account self-medication, rare in this context, nor the fact that some patients might buy medications and not consume them; actual use of the medications, however, is certainly more likely when medications have been purchased repeatedly than when drug consumption is accounted for on the sole basis of declaration of prescriptions by doctors or a fortiori patient self-declaration. It should be noted that all MI patients can get full health coverage for their disease management. During acute care or long-term hospitalization, as with public institutionalization, medications are included in hospital costs without it being possible to identify them. For this reason, in part, we included patients 6 months after their index hospitalization for MI, but we may have underestimated adherence for the oldest people in long-stay hospitals or public institutions for dependent old people. Finally, the medico-administrative nature of the databases does not permit adjustment for certain specific clinical factors, such as those specifying the extent or severity of the disease. Nevertheless, diagnosis of comorbidities was strengthened by data on specific medication reimbursement and full coverage for these long-term chronic diseases. Indication bias should be considered, with characteristics and clinical differences between those with a higher or lower (for long-term prevention) risk of death according to clinical status and comorbidities. Thus, results were adjusted for patients' characteristics and myocardial revascularization procedures. Survivor treatment selection bias and competing medical issues are unlikely to affect our results because the classical effect of each medication and adherence was apparent. Good adherence could be a surrogate for other factors that reflect a high quality of care, healthy behaviours or more effective treatment. A dose effect for adherence was assessed by studies on betablockers and statins [12] .
Conclusions
This study showed that 50% of patients had good adherence to combined EBT 30 months after MI. Good adherence to EBT and combination treatment was associated with a reduction in all-cause mortality and ACS admission among patients. The survival and readmission benefits of combined EBT and the factors found to be associated with adherence emphasize the importance of promoting EBT among specific population groups.
